Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...

Kyverna reports one-year Phase II data for miv-cel in stiff person syndrome and plans a rolling BLA filing. Read the full ...

Hologic signs deal to acquire Barcelona-based Reveal Genomics, expanding breast cancer diagnostics to complement its BCI test. Read the full deal details.

Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...

Olorofim meets its non-inferiority goal against AmBisome in the Phase III OASIS trial for invasive aspergillosis. Read full ...

Curis prices an $8.5M private placement at $0.51 per share to fund emavusertib CLL data in December 2026. Read the full story on the offering and runway.

Alcon acquires Neurotech for USD 550m, gaining ENCELTO, the only FDA-approved MacTel type 2 cell therapy. Read how it expands Alcon's retina portfolio.

City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...

Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.

Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...

Lilly's Omvoh met its Phase III primary endpoint in pediatric ulcerative colitis, with 50% of responders in remission at Week ...

Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.